R
Raúl J. Andrade
Researcher at University of Málaga
Publications - 340
Citations - 16338
Raúl J. Andrade is an academic researcher from University of Málaga. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 54, co-authored 282 publications receiving 13305 citations. Previous affiliations of Raúl J. Andrade include University of Barcelona & Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu,Vlad Ratziu,Stephen A. Harrison,Sven Francque,Pierre Bedossa,Philippe Lehert,Philippe Lehert,Lawrence Serfaty,Manuel Romero-Gómez,Jérôme Boursier,Manal F. Abdelmalek,Steve Caldwell,Joost P.H. Drenth,Quentin M. Anstee,Dean W. Hum,Rémy Hanf,A. Roudot,S. Megnien,Bart Staels,Arun J. Sanyal,Philippe Mathurin,J. Gournay,Eric Nguyen-Khac,V. de Ledinghen,Dominique Larrey,A. Tran,M. Bourliere,M. Maynard-Muet,Tarik Asselah,Jean Henrion,Frederik Nevens,David Cassiman,Albert Geerts,Christophe Moreno,Ulrich Beuers,Peter R. Galle,Ulrich Spengler,Elisabetta Bugianesi,Antonio Craxì,Mario Angelico,Silvia Fargion,M. Voiculescu,Liana Gheorghe,L. Preotescu,Juan Caballería,Raúl J. Andrade,Javier Crespo,J. L. Callera,Aftab Ala,Guruprasad P. Aithal,G. Abouda,Velimir A. Luketic,M. A. Huang,Stuart C. Gordon,Paul J. Pockros,Fred Poordad,N. Shores,M. W. Moehlen,Kiran Bambha,V. Clark,Sanjaya K. Satapathy,S. Parekh,R. K. Reddy,Muhammad Y. Sheikh,Gyongyi Szabo,John M. Vierling,T. Foster,Guillermo E. Umpierrez,C. Chang,Terry Box,J. Gallegos-Orozco +70 more
TL;DR: A post-hoc analysis of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat analysis and in patients with moderate or severe NASH.
Journal ArticleDOI
Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period
Raúl J. Andrade,M. Isabel Lucena,M. Carmen Fernández,G. Pelaez,Ketevan Pachkoria,Elena García-Ruiz,B. García-Muñoz,Rocío González-Grande,Angeles Pizarro,José Antonio Durán,Manuel Jimenez,Luis Rodrigo,Manuel Romero-Gómez,J.M. Navarro,Ramon Planas,Joan Costa,Africa Borras,Aina Soler,Javier Salmerón,Rafael Martín-Vivaldi +19 more
TL;DR: Patients with drug-induced hepatocellular jaundice have 11.7% chance of progressing to death or transplantation, and amoxicillin-clavulanate stands out as the most common drug related to DILI.
Journal Article
Drug-induced hepatotoxicity.
Raúl J. Andrade,M.I. Lucena +1 more
TL;DR: The influence of older age in the cholestatic/mixed expression of the liver injury, as well as the independent association of female gender, older age, aspartate aminotransferase levels/hepatocellular type of damage and high bilirubin levels with the risk of fulminant liver failure/death are underlined.
Journal ArticleDOI
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
Manuel Romero-Gómez,M.M. Viloria,Raúl J. Andrade,Javier Salmerón,Moisés Diago,Conrado M. Fernández-Rodríguez,Raquel Corpas,Marina Cruz,L. Grande,Luis Vázquez,Paloma Muñoz-de-Rueda,Pilar López-Serrano,A. Gila,Maria Luisa Gutierrez,Celia Perez,Angela Ruiz-Extremera,E. Suárez,Jesús Castillo +17 more
TL;DR: Insulin resistance, fibrosis, and genotype are independent predictors of the response to antiviral therapy in chronic hepatitis C patients treated with peginterferon plus ribavirin.
Journal ArticleDOI
Case definition and phenotype standardization in drug-induced liver injury
Guruprasad P. Aithal,Paul B. Watkins,Raúl J. Andrade,Dominique Larrey,Mariam Molokhia,Hajime Takikawa,Christine M. Hunt,Russell A. Wilke,Mark I. Avigan,Neil Kaplowitz,Einar Björnsson,Ann K. Daly +11 more
TL;DR: An international DILI Expert Working Group of clinicians and scientists reviewed current DILi terminology and diagnostic criteria so as to develop more uniform criteria that would define and characterize the spectrum of clinical syndromes that constitute D ILI.